Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2025-01-27 00:00:00 ET · period of report 2025-01-23 · accession 0000950170-25-009204 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-01-27 | 2025-01-23 | KLRS | Hagen Brett R | CAO | S - Sale | $9.50 | -36 | 2,932 | -1% | -$342.16 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-23 | S | D | 4 | $9.94 | 2,928 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. (F3) Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025. |
| 2 | Common | Common Stock | 2025-01-23 | S | D | 32 | $9.45 | 2,932 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. (F3) Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025. |